H
Hanyun Ren
Researcher at Peking University
Publications - 115
Citations - 1596
Hanyun Ren is an academic researcher from Peking University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 15, co-authored 100 publications receiving 1084 citations. Previous affiliations of Hanyun Ren include Peking Union Medical College Hospital.
Papers
More filters
Journal ArticleDOI
Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial
Frits van Rhee,Raymond S.M. Wong,Nikhil C. Munshi,Jean-François Rossi,Xiaoyan Ke,Alexander Fosså,David Simpson,Marcelo Capra,Ting Liu,Ruey Kuen Hsieh,Yeow Tee Goh,Jun Zhu,Seok-Goo Cho,Hanyun Ren,James Cavet,Rajesh Bandekar,Margaret Rothman,Thomas A. Puchalski,Manjula Reddy,Helgi van de Velde,Jessica Vermeulen,Corey Casper +21 more
TL;DR: Siltuximab plus best supportive care was superior tobest supportive care alone for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged exposure.
Journal ArticleDOI
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Lan-Ping Xu,Hu Chen,Jing Chen,Mingzhe Han,He Huang,Yongrong Lai,Dai-Hong Liu,Qifa Liu,Ting Liu,Ming Jiang,Hanyun Ren,Yongping Song,Zimin Sun,Jianmin Wang,Depei Wu,Daobin Zhou,Ping Zou,Kai-Yan Liu,Xiao-Jun Huang,Xiao-Jun Huang +19 more
TL;DR: The consensus on routine practices of all-HSCT in China is summarized and the recommendations of indications, conditioning regimen, and donor selection are focused on.
Journal ArticleDOI
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.
Xiao-Hui Zhang,Jing Chen,Mingzhe Han,He Huang,Erlie Jiang,Ming Jiang,Yongrong Lai,Dai-Hong Liu,Qifa Liu,Ting Liu,Hanyun Ren,Yongping Song,Zimin Sun,Xiaowen Tang,Jianmin Wang,Depei Wu,Lan-Ping Xu,Xi Zhang,Daobin Zhou,Xiao-Jun Huang,Xiao-Jun Huang +20 more
TL;DR: The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization of clinical practices of allo-HCT in China and progressive integration with the world as discussed by the authors.
Journal ArticleDOI
Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
Jie Jin,Jianxiang Wang,Feifei Chen,Depei Wu,Jiong Hu,Jian-Feng Zhou,Jianda Hu,Jianmin Wang,Jian-Yong Li,Xiao-Jun Huang,Jun Ma,Chunyan Ji,Xiao-Ping Xu,Kang Yu,Hanyun Ren,Yu-Hong Zhou,Yin Tong,Yinjun Lou,Wan-Mao Ni,Hongyan Tong,Huafeng Wang,Yingchang Mi,Xin Du,Bao-An Chen,Yi Shen,Zhu Chen,Sai-Juan Chen +26 more
TL;DR: The proportion of patients who achieved complete remission after two cycles of induction treatment and event-free survival in the intention-to-treat population were the primary endpoints.
Journal ArticleDOI
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial
Hong-Hu Zhu,Depei Wu,Xin Du,Xi Zhang,Lin Liu,Jun Ma,Zong-Hong Shao,Hanyun Ren,Jianda Hu,Kai-Lin Xu,Jing-Wen Wang,Yongping Song,Mei-Yun Fang,Juan Li,Xiao-Yan Yan,Xiao-Jun Huang +15 more
TL;DR: A pilot study of treatment with oral arsenic realgar-Indigo naturalis formula (RIF) plus ATRA without chemotherapy, which has a more convenient route of administration than the standard intravenous regimen, showed high efficacy, and non-inferiority was confirmed in the per-protocol population.